Biotoxtech Co., Ltd. acquired 60% stake in Sejong Venture Partners Co., Ltd. for KRW 3 billion.
March 13, 2013 at 09:30 am IST
Share
Biotoxtech Co., Ltd. (KOSE:A086040) acquired 60% stake in Sejong Venture Partners Co., Ltd. for KRW 3 billion on March 13, 2013. Biotoxtech Co. will acquire 0.6 million shares at a price of KRW 5000 per share. Sejong Venture Partners reported total assets and total common equity of KRW 5 billion for the year ended December 31, 2012. The Board of Directors of Biotoxtech Co. passed the resolution for the acquisition on March 13, 2013. The transaction is expected to be completed on March 13, 2013.
Biotoxtech Co., Ltd. (KOSE:A086040) completed the acquisition of 60% stake in Sejong Venture Partners Co., Ltd. on March 13, 2013.
Biotoxtech Co., Ltd. is a Korea-based company engaged in the research of non-clinical evaluation business. The Company provides safety evaluation research, efficacy evaluation research and analysis research. Its safety evaluation research business provides general toxicity tests, local toxicity tests, reproductive and development tests, genotoxicity tests, immunotoxicity tests, carcinogenicity tests, safety pharmacology tests, ecotoxicology tests, histopathology tests and hematology tests. Its efficacy evaluation research business provides efficacy evaluation of medical supplies, health supplements and cosmetics. Its analysis research business provides pharmacokinetics (PK) tests and toxicokinetics (TK) tests services, as well as validation and bio analysis services. On March 13, 2013, the Company acquired a 60% stake in its new established subsidiary.
BIOTOXTECH CO., LTD. 
